BEVACIZUMAB News

BEVACIZUMAB currently has 8 news articles, with 30 predicted indications.

This page combines the AI-predicted indications for BEVACIZUMAB with the latest health news. Indications highlighted in orange have recent news coverage.

Drug Information

Evidence level: L5
Predicted indications (30):
- hereditary breast carcinoma (99.0%)
- glioma susceptibility (99.0%)
- desmoplastic small round cell tumor (99.0%)
- metastatic malignant neoplasm in the colon (99.0%)
- glioblastoma (disease) (99.0%)
- cervical cancer (99.0%)
- primary peritoneal serous/papillary carcinoma (99.0%)
- breast cancer (99.0%)
- peritoneum cancer (99.0%)
- breast neoplasm (99.0%)
- primary peritoneal carcinoma (disease) (99.0%)
- undifferentiated carcinoma of the corpus uteri (99.0%)
- fallopian tube cancer (99.0%)
- cervical carcinoma (99.0%)
- squamous cell carcinoma of the corpus uteri (99.0%)
- malignant epithelial tumor of ovary (99.0%)
- fallopian tube carcinoma (99.0%)
- primary malignant peritoneal tumor (99.0%)
- hereditary breast ovarian cancer syndrome (99.0%)
- cervical adenocarcinoma (99.0%)
- epiglottis neoplasm (99.9%)
- benign neoplasm of tongue (99.9%)
- tumor of testis and paratestis (99.9%)
- benign neoplasm of hypopharynx (99.9%)
- benign neoplasm of floor of mouth (99.9%)
- cervical neuroblastoma (99.9%)
- cystic neoplasm (99.9%)
- nasal cavity inverting papilloma (99.9%)
- mesenchymoma (99.9%)
- schwannoma of jugular foramen (99.9%)